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Surgical Research in Patients
Ideal Time for an IDEAL Checklist
Jeffrey S. Barkun, MD, Justin B. Dimick, MD, MPH,y and Pierre-Alain Clavien, MD, PhDz
T he ability of surgeons to produce and publish high quality clinical research has been challengedon many occasions in past years. Arguably, the most widely remembered can be traced to The
Lancet, a journal launched in 1823 by Thomas Wakley:1 a surgeon intent on improving quality of
patient care. In the 1996 editorial entitled ‘‘Surgical research or comic opera: questions, but few
answers’’,2 Lancet editor Richard Horton cleverly, albeit bluntly, defied all surgeons to improve the
quality of the evidence in our journals. As a rebuke to this challenge, and under the leadership of
Jonathan L. Meakins, a series of meetings at Balliol College, Oxford in 2007–2008 brought together
surgeons as well as experts in evidence-based medicine, research design, and statistics, the challenge
being to reexamine research concepts which had previously been aimed at populational research or
the evaluation of medications in the post thalidomide era.3 The specific goal of the group was to adapt
these concepts to the daily, procedure-based surgical reality. The results of these meetings were
multifold: the acceptance by methodologists that Surgery is a complex intervention which cannot be
evaluated within the existing paradigm of drug treatments and the realization that evaluating surgery
involves the integration and documentation of strongly confounding factors such as multiple co-
interventions (anaesthesia, physiotherapy, etc. . .), learning curve effects, the ‘‘iterative process of
tinkering’’, technical expertise, and challenges of blinding the operator in clinical trials, to name a
few.4
The IDEAL recommendations and framework were originally proposed in a series of three
articles in the Lancet3–5 in 2009. These describe 5 consecutive stages which correspond to the stages
of development and dissemination of a new operative technique. Although they have been described
in detail elsewhere,6 each stage is characterized by posing a specific defining question, as summa-
rized in Table 1 below.
IDEAL proposes stage-specific optimal research designs and outcomes to evaluate the new
treatment, ranging from case reports (stage 1) to Randomized Clinical Trials (‘‘RCTs’’), and then
registries (stage 4). The key evaluation remains a large multi-center, multi surgeon RCT in stage 3,
understanding that in some instances, such a RCT may not be feasible or desirable. It should be
attempted if at all possible because results are not always predictable, as once again demonstrated by
the oncological outcomes of a recent large multi-center RCT comparing minimally invasive to open
radical hysterectomy for early-stage cervical cancer, which surprisingly found lower 5-year survival
with the minimally invasive approach.7
Based on a two-round, on-line delphi process, two broad-based conferences in Oxford in 2016
and New York in 2017 have added to IDEAL, and are reported in this issue of the Annals of
Surgery.8,9 The first addresses a key point to better operationalize IDEAL10 by adding a PICO system
to distinguish which stage most accurately characterizes the new treatment at the time of the
evaluation and which endpoints need to be reached prior to moving to the next stage.8 ’’P’’
(population) describes how many patients and surgeons (or operators) are currently undergoing/
using the new technique, ‘‘I’’ (intervention) addresses how mature are the details of the intervention,
‘‘C’’ (comparator) speaks to the gold standard which the new technology is trying to replace, and ‘‘O’’
(outcomes) are the outcomes, which have already been documented to date and those remaining to
document for the current IDEAL stage. In addition, in order to broaden the scope of application of
IDEAL, extensions have been proposed: ‘‘Pre-IDEAL’’ to address the evaluation of pre-clinical
studies prior to ‘‘first in human’’ trials; these may include material testing, simulator, cadaver, animal,
modelling and cost-effectiveness studies. Other specialized variants include IDEAL-D to evaluate
therapeutic devices, or extensions for multiple specific clinical domains such as the R-IDEAL tool
from the MRI-Linear Accelerator Consortium11 and the IDEAL-Physio extension in physiotherapy.8
In the second report in this issue,9 ethical considerations are given center stage with a view to
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minimizing harm to patients, especially during learning curves, all
the while respecting patient autonomy and ensuring equitable access
to innovations.
Since its introduction a decade ago, there is increasing evi-
dence that the IDEAL approach has been broadly embraced by the
surgical community. As of October 2017, a total of 552 papers had
cited key IDEAL reports.8 A paper in the current issue of the Annals
of Surgery covers the evolving learning curves in laparoscopic liver
surgery according to descriptions of surgeons in stages 2 and 3 of the
IDEAL paradigm.12 Another example is the evaluation of the
challenging 2-stage ‘‘ALPPS’’ procedure (‘‘associating liver parti-
tion and portal vein ligation for staged hepatectomy’’) which was
described 10 years ago.13 ALPPS14 may enable the curative removal
of otherwise unresectably large liver tumors, but has been found to be
associated with high morbidity. This innovative procedure has also
been consistently reported according to the IDEAL stages.15
There is increasing acceptance of IDEAL among health care
decider communities internationally: the Medical Device Epidemi-
ology Network Initiative (MDEpiNet) partnership with the US Food
and Drug Administration (FDA);16 EXCITE: an international con-
sortium offering device manufacturers a comprehensive assessment
service for innovative new products; and the European Network for
Health Technology Assessment (EUnetHTA National Institute of
Healthcare Research) in the UK which recommends IDEAL study
designs in commissioning briefs.8
Given the seemingly wide-ranging consensus to accept this
framework for the evaluation of new surgical technology, what would
be the next steps to continue to meet Richard Horton’s challenge head
on? The moment certainly appears to be ripe for Surgery. Seen in a
broader perspective, the blooming of IDEAL embodies a significant
underlying paradigm shift: until the 70’s-80’s, formal surgical
research training and tools consisted essentially of assays and wet
lab exposure with the quality of clinical work being assessed
primarily through institutional mortality/morbidity rounds,17 in the
tradition of E. Codman,18 as well as by the publication of case reports
and retrospective case series. Other than a few notable cases, surgery
initially seemed to be left out of the evidence-based revolution,19 as
shown by the penetration of RCT’s in the surgical literature estimated
to have been consistently less than 10% in 1995 and 2006.20,21 Flash
forward to 2018 when a random sampling of surgical literature22
suggests this figure may have tripled or even quadrupled. What’s
more, even if the quality of published surgical research may not be
convincingly on the upswing,23,24 the potential and the tools to
advance it are solidly in place. Unlike their predecessors, mainstream
clinical researchers in surgery are currently able to call upon a
multitude of validated or consensus-driven tools to address most
aspects of performing, measuring, and reporting clinical surgical
research. These tools are complementary to the framework proposed
by IDEAL and represent the next generation of ‘‘assays’’ in modern
surgical clinical research. They include generic outcome measures
such as the Clavien-Dindo25,26 classification, or comprehensive
complication index (CCI)27 for morbidity/mortality, and proce-
dure-specific validated measures such as the classification for
delayed gastric emptying after pylorus-preserving pancreaticoduo-
denectomy by the international Study Group of Pancreatic Surgery.28
The COMET initiative is committed to the development and appli-
cation of agreed standardized sets of outcomes, known as ‘‘core
outcome sets’’.29 We surgeons also have our own surgery-specific,
technically-intensive RCT designs such as ‘‘expertise-based trials’’
where patients are randomized to a single surgeon performing a
single procedure rather than multiple surgeons performing more than
one procedure which they may not fully master or believe in.30 We
even have a grid to evaluate if a published RCT truly fits our practice
(‘‘Applicability Scoring of Surgical trials’’).31
The EQUATOR Network promotes transparent and accurate
reporting and a wider use of reporting guidelines in biomedical
science.32 Its sponsors keep track of a plethora of reporting standards
many of which are fine-tuned for surgical practice such as the
CONSORT statement for non-pharmacological randomized stud-
ies),33 which addresses the documentation of variables known to
be important in surgery rather than drug trials, especially in stage 3.
Examples are ‘‘details of the intervention and comparator as they
were implemented’’, and ‘‘a description of care providers; case
volume, qualification, expertise and centers volume in each
group. . .’’. The (TIDieR) checklist and guide (‘‘template for inter-
vention description and replication’’34 is committed to the better
reporting of interventions by describing these in sufficient detail to
allow their replication, essential in IDEAL stages 2 and 2a. The
SCARE statement and checklist applies to surgical case reports such
as are needed in stages 1 and 2 of IDEAL.35 EQUATOR also tracks
proposed reporting guidelines for newer methodologies which are
increasingly popular in surgery such as the proposed Reporting and
Guidelines in Propensity Score Analysis used in Cancer Surgical
Studies,36 or CONSORT and STROBE statement extensions in
simulation research.37
With all these surgery-specific pieces in place, what can the
Annals of Surgery do to help its readership bring our literature to the
next level?
A strategy would be for journal editors to make the IDEAL
framework a mandatory part of the submission process. Authors
submitting publications that evaluate new surgical procedures and
technology could use a series of checklists to identify the IDEAL
stage and then note the presence or absence of important design
features in the conduct and reporting of their study. There is a
precedent for this type of structured checklist assessment as part
of the submission process. The CONSORT guidelines for reporting
TABLE 1. Questions Related to Each Stage of the IDEAL Framework
Stage Question
Idea
Stage 1
What is the new treatment concept and why is it needed?
Development
Stage 2a
Has the new intervention reached a state of stability sufficient to allow replication by others?
Exploration
Stage 2b
Have the questions that might compromise the chance of conducting a successful Randomized Clinical Trial been addressed?
Assessment
Stage 3
How does the new intervention compare with current practice?
Long-term study
Stage 4
Are there any long-term or rare adverse effects or changes in indications or delivery quality over time?
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randomized clinical trials have been widely used.38,39 The checklist
is part of the instructions for authors and completing the checklist is
mandatory at many journals.
Peer reviewers have access to this checklist to compare
the design features of the trial with recommended best
practices. Although it is difficult to measure the impact of
this checklist in improving the quality of clinical trials, there is
compelling evidence that it improves the quality of reporting key
elements of design.40
To implement this strategy for the IDEAL framework, specific
checklists of best practices in conduct and reporting would still need
to be developed for each IDEAL stage. This editorial should thus be
seen as a not-so-cleverly disguised challenge to develop such a set of
IDEAL checklists in order to permit us to definitively write the last
act of our surgical comic opera.
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